Brendan Rory Barber MBChB, Presenter: Nothing to Disclose

Mark Ingram MBBS, Abstract Co-Author: Nothing to Disclose

Sameer Khan, Abstract Co-Author: Nothing to Disclose

Gul Bano, Abstract Co-Author: Nothing to Disclose

Ioannis Vlahos MBBS, Abstract Co-Author: Researcher, Siemens AG Consultant, Siemens AG Consultant, General Electric Company Consultant, Medicsight, Inc

The discovery of SDH mutations has changed the genetic work up of patients with paragangliomas. We aim to: Review the relationship between SDH mutations and the paraganglioma syndromes Discuss the radiological presentation of the various mutations Review the recent suggestions for radiological screening and surveillance  

Summary of the role of SDH and its role in tumorogenesis Review of the imaging findings and characteristics of the various tumors on CT, MRI and angiography Anticipated clinical presentation of the succinyl dehydrogenase mutations according to SDH mutation, including: age of presentation, tumour location, multifocality, neoplastic potential and disease progression Screening and Surveillance protocols following diagnosis of SDH mutations in the patient or a relative  

Clinical differences have been established between the various SDH mutation carriers. The teaching points of this exhibit are: Relationship between SDH mutations and paraganglioma syndromes Radiological differences between SDH mutation presentation Recent suggestions for imaging surveillance protocols  

Barber, B, Ingram, M, Khan, S, Bano, G, Vlahos, I, Paragangliomas and Succinyl Dehydrogenase (SDH) Mutations: The Imaging of Newly Discovered Important Mutation Populations.  Radiological Society of North America 2011 Scientific Assembly and Annual Meeting, November 26 - December 2, 2011 ,Chicago IL. http://archive.rsna.org/2011/11009629.html